This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is the first clinical study in HCV-infected subjects with BMS-605339. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and antiviral activity of BMS-605339 following single oral doses of 10 to 400mg in HCV-infected subjects.
Showing the most recent 10 out of 370 publications